(Q38782659)

6 September 2017

title

Astragaloside IV, a Natural PPARγ Agonist, Reduces Aβ Production in Alzheimer's Disease Through Inhibition of BACE1. (English)

1 reference

6 September 2017

0 references

Xu Wang

1

1 reference

6 September 2017

Yue Wang

2

1 reference

6 September 2017

Jiang-Ping Hu

3

1 reference

6 September 2017

Song Yu

4

1 reference

6 September 2017

Bao-Kun Li

5

1 reference

6 September 2017

Yong Cui

6

1 reference

6 September 2017

Lu Ren

7

1 reference

6 September 2017

Li-De Zhang

8

1 reference

6 September 2017

publication date

29 March 2016

1 reference

6 September 2017

published in

Molecular Neurobiology

1 reference

6 September 2017

volume

54

1 reference

6 September 2017

issue

4

1 reference

6 September 2017

page(s)

2939-2949

1 reference

Fluorimetric detection of the earliest events in amyloid β oligomerization and its inhibition by pharmacologically active liposomes.

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

APP intracellular domain derived from amyloidogenic β- and γ-secretase cleavage regulates neprilysin expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

Reassessing the amyloid cascade hypothesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

Shared links between type 2 diabetes mellitus and Alzheimer's disease: A review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

The Nuclear Receptor PPARgamma as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

Glimepiride attenuates Aβ production via suppressing BACE1 activity in cortical neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

Use of pioglitazone in the treatment of diabetes: effect on cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

Down-regulation of PERK-ATF4-CHOP pathway by Astragaloside IV is associated with the inhibition of endoplasmic reticulum stress-induced podocyte apoptosis in diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

Astragaloside IV ameliorates diabetic nephropathy involving protection of podocytes in streptozotocin induced diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

Effects of astragaloside IV on pathogenesis of metabolic syndrome in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

Ameliorating the effect of astragaloside IV on learning and memory deficit after chronic cerebral hypoperfusion in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

Protective effects of astragaloside IV against amyloid beta1-42 neurotoxicity by inhibiting the mitochondrial permeability transition pore opening

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

BACE1 gene promoter single-nucleotide polymorphisms in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

Astragaloside IV prevents MPP⁺-induced SH-SY5Y cell death via the inhibition of Bax-mediated pathways and ROS production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

Astragaloside IV inhibits microglia activation via glucocorticoid receptor mediated signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

Protective effects of astragalosides on dexamethasone and Aβ25-35 induced learning and memory impairments due to decrease amyloid precursor protein expression in 12-month male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer's disease and mild-to-moderate Alzheimer's disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

Effect of pioglitazone medication on the incidence of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

PPARγ agonist pioglitazone reverses memory impairment and biochemical changes in a mouse model of type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

Ginsenoside Rg1 attenuates β-amyloid generation via suppressing PPARγ-regulated BACE1 activity in N2a-APP695 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

The resveratrol trimer miyabenol C inhibits β-secretase activity and β-amyloid generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

Advanced glycation end products induce oxidative stress and mitochondrial dysfunction in SH-SY5Y cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

Trientine reduces BACE1 activity and mitigates amyloidosis via the AGE/RAGE/NF-κB pathway in a transgenic mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-016-9874-6

10.1007/S12035-016-9874-6

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

6 September 2017

1008163560

0 references

1 reference